

Dr Jeremy Rees PhD FRCP

Consultant Neurologist
National Hospital for Neurology and
Neurosurgery
Queen Square
London WC1N 3BG

Tel: 020 3448 4156
PA: 020 3448 3782
Fax: 020 3448 8994
E-mail: Jeremy.rees@ucl.ac.uk

GMC Number: 3196139

- Honorary Senior Lecturer, UCL Institute of Neurology
- Consultant Neurologist Royal National Orthopaedic Hospital and Mount Vernon Cancer Centre

QUALIFICATIONS:

1985 **BSc (Hons) Advanced Neuroanatomy and Neuropharmacology**, 1st Class, Middlesex Hospital Medical School, London

1988 **MB BS with distinction in Medicine, Surgery, Clinical Pharmacology & Therapeutics**
University College and Middlesex School of Medicine, London

1991 **MRCP (UK)**

1995 **PhD for thesis entitled: “*Campylobacter jejuni and Guillain-Barre syndrome*”,**
Department of Neurology, Guy’s Hospital, United Medical Dental School, London

2003 **FRCP**

CURRENT RESEARCH GRANTS:

2014-2019 Brain Tumour Research Charity “*Epigenome of neural stem cells and high grade gliomas*”
Principal Clinical Investigator. (£3,317,208)

2017 – 2021 The Brain Tumour Charity and Brain Tumour Research Charity “*Diffusion Imaging in Gliomas*”
Co Applicant (£215,000)

EDUCATION:

2008-2011 Lead consultant for Neurology at National Hospital, Queen Square

2009-2011 Module Lead Clinical Neurosciences

2011 – present Neurology SSC lead

2017-18 Organiser Queen Square Multidisciplinary Course

Lecturer and Examiner on Taught Masters Courses – Neurosciences, Advanced Imaging, Clinical Neurology, Oncology, Neurodegenerative Disease

ADVISORY ROLES:

2016- 2018 NICE Guidelines Committee for Brain Tumour Treatments

2016- 2019 ABN Advisory Committee for Neuro-oncology

ACADEMIC SUPERVISION

- 2017 L Rice MRI Features Predictive of Genotype and Survival In Astrocytomas (MSc)
2012 F Teo A ten year follow-up of patients with untreated low-grade gliomas (MSc)
2010 J Czerny. Prognostic factors in low-grade gliomas. (MSc)
2009 N Potter. Cytogenetic and microarray analysis of paediatric astrocytoma (PhD)

LEADERSHIP ROLES:

- 2011 - 2015 Brain Cancer Clinical Pathway Director, London Cancer
2010 - 2013 Clinical Lead for Brain Tumour Unit at UCLH/NHNN
2010- 2018 Treasurer and Executive Council Member, British Neuro-oncology Society

PUBLICATIONS:

Textbook

Neuro-oncology eds **Jeremy Rees** and Patrick Wen. Elsevier, 2010

Book Chapters

1. 'Drugs in Neuro-oncology' Ledingham D and **Rees JH**. in *Drugs in Neurology* eds Nageshwaran S, Ledingham D and Wilson HC. Oxford University Press 2017
2. 'Neuro-oncology' **JH Rees**, HR Jager, N Fersht, S Brandner, R Bradford and E Wilson *Queen Square Textbook 2nd Edn*, eds Clark, Shorvon, Rossor, Howard. Blackwell, 2016
3. 'Brain Tumours' and 'Paraneoplastic Neurological Syndromes' **JH Rees** *Oxford Textbook of Medicine 6th Edn*; eds Warrell, Cox, Firth and Benz. Oxford, 2018

Recent Peer Reviewed Publications

1. Apparent Diffusion Coefficient for Molecular Subtyping of non-gadolinium-enhancing WHO II/III glioma: volumetric segmentation versus two-dimension region of interest analysis. Thust SC, Hassanein S, Bisdas S, **Rees JH** et al. *Eur Radiol* 2018;Mar 23 doi: 10.1007/s00330-018-5351-0. [Epub ahead of print]
2. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Baumert B, Hegi MR, van den Bent M et al. *Lancet Oncology* 2016;17: 1522-1532
3. Acute demyelination following radiotherapy for glioma: a cautionary tale. Milic M, **Rees JH** *Practical Neurology* 2017; 17: 35-38
4. Diagnostic delay and survival in high grade gliomas – evidence of the “waiting time paradox”? Aggarwal A, Herz N, Campbell P, Arkush L, Short S, **Rees J**. *Br J Neurosurg* 2015 ; 4: 1-4

Reviews

Advanced MRI techniques in the monitoring of treatment of gliomas. Hyare H, Thust S, **Rees J**. *Current Treatment Options in Neurology*. 2017; 19:11